Prognostic factors for surgical treatment of radiation-induced scleral necrosis after brachytherapy for uveal melanoma.

Scleral necrosis brachytherapy severity scale uveal melanoma

Journal

European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772

Informations de publication

Date de publication:
29 May 2024
Historique:
medline: 29 5 2024
pubmed: 29 5 2024
entrez: 29 5 2024
Statut: aheadofprint

Résumé

Radiation-induced scleral necrosis (RISN) is a less frequent complication of brachytherapy for uveal melanoma, and may require surgical treatment in selected cases. We aimed to identify the prognostic factors for RISN treatment. All patients with brachytherapy for uveal melanoma treated at our institution between 01/1999 and 12/2016 who developed RISN were followed until 02/2021. Various parameters were evaluated through univariable and multivariable Cox regression analysis. The surgical intervention due to RISN was the principal outcome event of this study. Of 115 patients in the final cohort, 51 individuals (44%) underwent RISN treatment (conjunctival revision [n = 2], patching [n = 46] or enucleation [n = 3]) at median 1.80 months after RISN occurrence. Significant RISN characteristics were summarized into a novel RISN severity scale - Grade I: largest diameter ≤ 5 mm and no progression; Grade II: largest diameter > 5 mm or any progression during the follow-up; Grade III: presence of uveal prolapse; and Grade IV: leakage through open eyewall perforation. In the multivariable analysis, the RISN severity scale (aHR = 2.37 per grade increase, p = 0.01) and the time between brachytherapy and RISN occurrence (<15 months, aHR = 6.33, p < 0.0001) were independently associated with the study endpoint. The RISN severity scale showed high diagnostic accuracy for prediction of RISN treatment (AUC = 0.869). In our series, about the half of RISN cases underwent surgical treatment. The presented novel severity scale for RISN might become a helpful tool for clinical management of individuals with RISN. We recommend external validation of the diagnostic accuracy of the presented scale.

Identifiants

pubmed: 38807558
doi: 10.1177/11206721241257979
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

11206721241257979

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Leyla Jabbarli (L)

Department of Ophthalmology, University Hospital, Essen, Germany.

Eva Biewald (E)

Department of Ophthalmology, University Hospital, Essen, Germany.

Maja Guberina (M)

Department of Radiotherapy, University Hospital Essen, Germany.

Philipp Rating (P)

Department of Ophthalmology, University Hospital, Essen, Germany.

Miltiadis Fiorentzis (M)

Department of Ophthalmology, University Hospital, Essen, Germany.

Dirk Flühs (D)

Department of Radiotherapy, University Hospital Essen, Germany.

Claudia H D Le Guin (CHD)

Department of Ophthalmology, University Hospital, Essen, Germany.

Ekaterina Sokolenko (E)

Department of Ophthalmology, University Hospital, Essen, Germany.

Wolfgang Sauerwein (W)

Department of Radiotherapy, University Hospital Essen, Germany.

Norbert Bornfeld (N)

Department of Ophthalmology, University Hospital, Essen, Germany.

Martin Stuschke (M)

Department of Radiotherapy, University Hospital Essen, Germany.
German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Heidelberg, Essen, Germany.

Nikolaos E Bechrakis (NE)

Department of Ophthalmology, University Hospital, Essen, Germany.

Classifications MeSH